Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$101.0K+67.59%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Motti Farbstein
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Beta
- 0.02
- Country
- IL
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -33.97
Financials
Revenue
$101.0K+67.6%Net Income
$-2.30MEBITDA
$-2.34MFree Cash Flow
$-2.66M-2068.5%EPS (diluted)
$-0.62Shares Outstanding (diluted)
3.71M-72.3%Operating Expenses
$2.44MCash & Debt
$7.04MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $408.2K | $-9.91M | $-0.08 |
| 2024 | $674.0K | $-7.88M | $-0.01 |
| 2023 | $743.0K | $-7.63M | $-0.01 |
| 2022 | $810.0K | $-10.17M | $-0.03 |
| 2021 | $853.0K | $-12.60M | $-0.06 |
| 2020 | $763.0K | $-14.44M | $-0.08 |
| 2019 | $2.03M | $-12.63M | $-0.30 |
| 2018 | $3.82M | $-6.57M | $-0.34 |
| 2017 | $844.7K | $-4.97M | $-0.38 |
| 2016 | $169.5K | $-6.90M | $-0.60 |
| 2015 | $164.7K | $-4.80M | $-0.54 |
| 2014 | $0.00 | $-6.10M | $-0.70 |
| 2013 | $0.00 | $-8.34M | $-1.22 |
| 2012 | $0.00 | $-5.57M | $-1.12 |
Valuation
CANFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+400.00%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·27d ago·Neutral
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
View source ↗ - Newsglobenewswire.com·28d ago·Positive
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
View source ↗ - Newsbenzinga.com·33d ago·Positive
Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study Can-Fite BioPharma Ltd. (NYSE:CANF) reported extended survival trends in a key late-stage cancer trial alongside a $4 million warrant exercise agreement to fund ongoing clinical operations.
View source ↗ - Newsglobenewswire.com·34d ago·Negative
…s Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggr…
View source ↗ - Newsglobenewswire.com·34d ago·Positive
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma Ramat Gan, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
View source ↗ - Newsglobenewswire.com·50d ago·Negative
…e's Ongoing Phase IIb Study Design Following Positive Phase IIa Results Ramat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced new preclinical findings demonstrating that namodenoson enhances the anti-cancer effect of gemcitabine chemotherapy in pancreatic cancer.
View source ↗ - Newsglobenewswire.com·55d ago·Negative
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs Ramat Gan, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, tod
View source ↗
Earnings
Thu, Apr 1(in 6 months)
Consensus estimate $-0.80 per share
Typical surprise +38.9% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Sep 8$-1.24 vs $-0.33miss
- Thu, Mar 26$-5.97 vs $-27.00beat
- Thu, Aug 28$-0.00 vs $-4.15beat
- Mon, Apr 14$-0.10 vs $-0.10beat
- Thu, Mar 27$-0.00 vs $-0.24beat
- Thu, Jan 2$-0.27 vs $-0.27beat
Estimates and results for CANF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CANF officers and directors.
No open-market trades in the recent filings. All 13 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
13 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CANF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.